Nerve-Calming amino acid may cut heart risk in kidney disease

NCT ID NCT03982160

Ongoing Knowledge-focused Sponsor: The University of Texas at Arlington Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether a single infusion of L-arginine, an amino acid, can reduce abnormally high sympathetic nerve activity in people with chronic kidney disease (CKD). High nerve activity is linked to increased cardiovascular risk in CKD patients. Researchers will measure nerve signals in the leg before and after the infusion to see if L-arginine helps lower this activity. The study involves 15 adults aged 35 to 75 with moderate CKD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: L-Arginine
What this could lead to: If successful, this could point toward a new way to lower cardiovascular risk in chronic kidney disease patients by calming an overactive nervous system.
What could go wrong: This is a small, early-phase study with only 15 participants, so results may not apply to all patients. The intervention is a single infusion, not a long-term treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC KIDNEY DISEASE

Contacts and locations

Locations

UT Southwestern

Dallas, Texas, 75390, United States
University of Delaware

Newark, Delaware, 19716, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.